Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – ®– Preliminary Unaudited Full Year 2025 Total Revenue and U.S. XPOVIO (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $115 Million, Respectively – NEWTON, Mass., Jan. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel ...